The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

The final appraisal document for Dupixent (dupilumab) has given the green light ... It is the second indication for the IL-4 and IL-13 inhibitor cleared for use by the NHS in England and Wales ...

Sanofi SNY and Regeneron’s REGN Dupixent (dupilumab), an injectable monoclonal antibody that blocks IL-4/IL-13 signaling, is an approved therapy for multiple allergic and atopic diseases.

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...